Iovance Biotherapeutics (IOVA)
(Delayed Data from NSDQ)
$11.87 USD
+0.25 (2.15%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $11.82 -0.05 (-0.42%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Earnings News For IOVA
-
Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View
-
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates
-
Iovance Biotherapeutics: Q2 Earnings Snapshot
-
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024
-
Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates
-
Iovance Biotherapeutics: Q1 Earnings Snapshot
-
Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
-
Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect
-
Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?
-
Iovance's (IOVA) Q4 Earnings & Sales Fall Short of Estimates
-
Iovance Biotherapeutics: Q4 Earnings Snapshot
-
Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Misses Revenue Estimates
-
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
-
Why Is Iovance Biotherapeutics (IOVA) Up 53% Since Last Earnings Report?
-
Iovance's (IOVA) Meets Q3 Earnings, Lags Sales Estimates
-
Iovance Biotherapeutics: Q3 Earnings Snapshot
-
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates
-
Why Is Iovance Biotherapeutics (IOVA) Down 21.2% Since Last Earnings Report?
-
Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q2
-
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates
-
Iovance Biotherapeutics: Q2 Earnings Snapshot
-
Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates
-
Why Is Iovance Biotherapeutics (IOVA) Up 7.9% Since Last Earnings Report?
-
Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q1